Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 6/20 | 0.57 |
| ▸ | AVPR1A | P37288 | 5/20 | 0.57 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.57 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.57 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3366380 | 1.00 | OXTR (0.57) | OXTRAVPR1AAVPR2AVPR1BPTGER1 | |
| SCHEMBL3365022 | 0.86 | OXTR (0.49) | OXTRAVPR1APTGER1ALDH1A1RAB9A | |
| SCHEMBL3365025 | 0.86 | OXTR (0.49) | OXTRAVPR1APTGER1ALDH1A1RAB9A | |
| SCHEMBL3366267 | 0.85 | OXTR (0.54) | OXTRAVPR1AALDH1A1MEN1KMT2A | |
| SCHEMBL3367832 | 0.85 | OXTR (0.54) | OXTRAVPR1AALDH1A1MEN1KMT2A | |
| SCHEMBL3366527 | 0.84 | RAB9A (0.45) | OXTRAVPR1AAVPR2AVPR1BPTGER1 | |
| SCHEMBL3366436 | 0.84 | RAB9A (0.45) | OXTRAVPR1AAVPR2AVPR1BPTGER1 | |
| SCHEMBL5641723 | 0.83 | MEN1 (0.51) | OXTRAVPR1APTGER1ALDH1A1MAPT | |
| SCHEMBL3366411 | 0.83 | MEN1 (0.51) | OXTRAVPR1APTGER1ALDH1A1MAPT | |
| SCHEMBL3366414 | 0.83 | MEN1 (0.51) | OXTRAVPR1APTGER1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335901-B1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | MERCK SERONO SA (CH) | 2010-04-14 | — | — | EP | claimed |
| US-7312358-B2 | Pharmaceutically active sulfanilide derivatives | LABORATOIRES SERONO SA (CH) | 2007-12-25 | — | — | US | claimed |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | MERCK SERONO SA (CH) | 2004-04-15 | — | — | US | claimed |
| EP-1335901-B1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | MERCK SERONO SA (CH) | 2010-04-14 | — | — | EP | disclosed |
| US-7312358-B2 | Pharmaceutically active sulfanilide derivatives | LABORATOIRES SERONO SA (CH) | 2007-12-25 | — | — | US | disclosed |
| US-7312358-B2 | Pharmaceutically active sulfanilide derivatives | LABORATOIRES SERONO SA (CH) | 2007-12-25 | — | — | US | disclosed |
| US-7312358-B2 | Pharmaceutically active sulfanilide derivatives | LABORATOIRES SERONO SA (CH) | 2007-12-25 | — | — | US | disclosed |
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | MERCK SERONO SA (CH) | 2004-04-15 | — | — | US | disclosed |
| EP-1335901-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | Applied Research Systems ARS Holding N.V. (AN) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002032864-A1 | PHARMACEUTICALLY ACTIVE SULFANILIDE DERIVATIVES | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2002-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072816-A1 | Pharmaceutically active sulfanilide derivatives | OXTR, AVPR2, OPRL1 | OXTR 1/4885AVPR1A 4/4885AVPR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.